<DOC>
	<DOC>NCT00317187</DOC>
	<brief_summary>The purpose of this study is to compare the reactogenicity &amp; safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.</brief_summary>
	<brief_title>Safety Study of a Vaccine Against Meningitis in Infants (2,4 &amp; 6 Months Age) After a Birth Dose of Hepatitis B.</brief_title>
	<detailed_description>Randomized study with four groups to receive one of the following vaccination regimens after a dose of hepatitis B vaccine given at birth: - One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologicals' Tritanrix™-HepB (3 different groups) - GSK Biologicals' Tritanrix™-HepB/Hiberix™</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criteria: • Healthy infants 5683 days of age at the time of the first vaccine dose, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks &amp; has received a birth dose of hepatitis B vaccine within the first 3 days of life. Exclusion criteria: Any confirmed immunodeficient condition, based on medical history and physical examination. Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period with the exception of oral polio vaccine (OPV). Use of any investigational or nonregistered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs since birth. Bacille CalmetteGuérin (BCG) vaccine received after the first 2 weeks of life. Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and/or meningococcal disease. History of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or meningococcal disease or known exposure to these diseases since birth. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>56 Days</minimum_age>
	<maximum_age>83 Days</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>